Conversations in Science With the Disruptors Leading the Way
Click the gear icon for captions in other languages.
Partnering With bit.bio for Translational Drug Development
Through a strategic partnership with bit.bio, Charles River provides clients access to a broadening bank of authentic human cells for use in target discovery, validation, and screening services. In drug discovery and safety, bit.bio’s unique ability to generate reprogrammable human cells at scale enables the development of therapies with a higher success rate among patients.
(Re)programming Stem Cells for Drug Development
Join Vital Science™ hosts Gina Mullane and Chris Garcia with Mark Kotter, Founder and CEO of bit.bio as they discuss technology to “reprogram” stem cells.
Listen to The Podcast